Uptake Uncertain for Potent New Cholesterol-Lowerer Inclisiran

Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its US debut in early 2022 with cautious uptake prospects.
Medscape Medical News

source https://www.medscape.com/viewarticle/967363?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost